Why XBiotech Inc.’s (XBIT) Stock Is Up 5.49%
As of Tuesday, October 27, XBiotech Inc.’s XBIT share price has surged by 5.49%, which has investors questioning if this is right time to sell.Tudor Pop
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
XBiotech Inc., a biopharmaceutical company, discovers, and develops, True Human monoclonal antibodies for treating various diseases. It develops a pipeline of product candidates targeting inflammatory and infectious diseases. The company is also developing interleukin-1 alpha therapies to various medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and general inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas.
Commentary & Analysis
Why XBiotech Inc.’s (XBIT) Stock Is Down 9.20%
As of Monday, October 19, XBiotech Inc.’s XBIT share price has dipped by 9.20%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why XBiotech Inc.’s (XBIT) Stock Is Down 6.21%
As of Thursday, August 13, XBiotech Inc.’s XBIT share price has dipped by 6.21%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why XBiotech Inc.’s (XBIT) Stock Is Up 6.89%
As of Thursday, March 19, XBiotech Inc.’s XBIT share price has surged by 6.89%, which has investors questioning if this is right time to sell.Jenna Brashear
Why XBiotech Inc.’s (XBIT) Stock Is Up 5.12%
As of Friday, March 13, XBiotech Inc.’s XBIT share price has surged by 5.12%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Financial Summary
| Share Statistics | XBIT | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $57.0 | $214.3 | 18% |
|
| Shares Out (Mil) | 30.5 | 53.9 | 37% |
|
| Institutional Ownership | 14.7% | 92.9% | 8% |
|
| Float (Mil) | 18.6 | 41.4 | 27% |
|
| Beta | 0.85 | 0.96 | 51% |
|
| Avg Daily Volume (000s) | 108 | 506 | 37% |
|
| Price Change (52-week) |
(13.4%) | 43.9% | 39% |
|
| Growth | XBIT | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.2% | na |
|
| Net Income (5yr) | (32.4%) | (10.1%) | 13% |
|
| EPS (5yr) | (32.6%) | 15.8% | 7 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | 36.9% | (15.7%) | 89% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | XBIT | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($45) | ($44) | 17% |
|
| EPS (TTM) | ($1.480) | ($1.500) | 17% |
|
| Operating Cash Flow (TTM) (Mil) | ($41) | ($34) | 11% |
|
| Net Cash Flow (TTM) (Mil) | na | $1 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 0% |
|
| Enterprise Value (Q1) (Mil) | ($39) | $172 | 1% |
|
| Valuation | XBIT | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.44 | 2.00 | 9% |
|
| P/E | na | 18.5 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | XBIT | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 67.3% | na |
|
| Net Margin | na | (63.5%) | na |
|
| ROA | (28.9%) | (47.5%) | 17% |
|
| ROE | (29.9%) | (53.3%) | 20% |
|
| Liabilities to Assets | 3.9% | 29.6% | 2% |
|
| F-Score | 2 | 2 | 7% |
|
Passing Stock Screens
As of 11/5/2026, from a list of 60 stock screening strategies,
GURU STRATEGY
Schloss Screen
Factors: Value, Quality
This screen looks for stocks hitting new lows, trading at a price lower than book value per share, with no debt and high levels of insider ownership.
| Performance Since Inception: | 2.6% |
| +/- S&P 500: | -4.8 |
